Why 80% of AI Health Platforms Fail VBC: Investor Alert

The promise of artificial intelligence in healthcare is vast, from accelerating drug discovery to personalizing treatment plans. Yet, when it comes to value-based care (VBC) arrangements, a critical gap emerges: the majority of AI health platforms currently fall short of the rigorous evidence and data requirements necessary to qualify. This readiness gap isn’t merely a hurdle; it represents a fundamental misalignment between the rapid innovation in AI health and the foundational principles of VBC, which demand demonstrable, auditable improvements in outcomes and cost efficiency.

The Unyielding Demands of Value-Based Care

Value-based care models, championed by organizations like CMS and CMMI, shift payment from volume to value, requiring providers and their technology partners to demonstrate improved patient outcomes and reduced costs. For AI health platforms to participate meaningfully in these arrangements, they must provide more than just promising algorithms or engaging user experiences. Payers, increasingly sophisticated in their VBC contract structures, demand a specific, robust evidence package. This typically includes:

• **Peer-Reviewed Outcomes Data:** Not just internal reports, but studies published in reputable, peer-reviewed journals, demonstrating clinical efficacy and patient benefit.
• **Auditable Return on Investment (ROI):** Clear, quantifiable financial performance metrics that prove cost reduction or avoidance, often over multi-year periods.
• **Performance Guarantees:** Contractual commitments from the AI vendor to achieve specific outcomes or financial targets, often with clawback provisions if targets are not met.
• **Multi-Year Data:** Evidence of sustained impact over extended periods, reflecting the chronic nature of many health conditions and the long-term goals of VBC.
• **Risk Adjustment Capabilities:** The ability to account for differences in patient populations and health statuses, ensuring fair comparisons and accurate attribution of savings.

Without these elements, AI health solutions, regardless of their technological sophistication, struggle to move beyond fee-for-service or pilot programs into the lucrative and expanding VBC landscape. As Eric Topol, a leading voice in digital medicine, frequently emphasizes, robust clinical validation is paramount for any new health technology. Eric Topol’s commentary on digital health validation

Hello Heart: A Blueprint for VBC Readiness

While many AI health platforms struggle to meet VBC requirements, a select few have successfully navigated this complex terrain. Hello Heart stands out as a notable example, demonstrating a comprehensive approach to evidence generation that aligns directly with payer needs for VBC contracts. Their strategy hinges on:

• **Extensive Peer-Reviewed Publications:** Hello Heart has consistently published its outcomes data in peer-reviewed journals, showcasing significant reductions in blood pressure, improvements in medication adherence, and other key cardiovascular metrics. These studies provide the clinical credibility payers demand.
• **Quantifiable Financial Performance:** Beyond clinical improvements, Hello Heart provides clear figures on cost savings. Their published research details reductions in healthcare utilization, such as emergency room visits and hospitalizations, directly translating to auditable ROI for health plans.
• **Performance Guarantees Backed by Data:** Leveraging their robust evidence base, Hello Heart is positioned to offer performance guarantees, mitigating risk for payers and demonstrating confidence in their platform’s ability to deliver tangible results.
• **Longitudinal Data Collection and Analysis:** Their platform is designed to collect and analyze multi-year data, allowing for a comprehensive understanding of sustained impact and providing the long-term evidence crucial for VBC arrangements.
• **Focus on Risk-Adjusted Outcomes:** Hello Heart’s approach inherently considers patient risk factors, ensuring that reported outcomes and cost savings are appropriately contextualized and attributed.

This methodical approach to evidence generation, exemplified by Hello Heart, provides a clear roadmap for other AI health companies aspiring to participate in VBC.

The VBC Readiness Gap: A Market Analysis

Rock Health’s analyses and industry observations suggest a significant disparity in VBC readiness across the AI health landscape. While companies like Omada Health and Hinge Health have made strides in demonstrating outcomes, many others, despite their substantial funding and user bases, have yet to produce the comprehensive evidence required for VBC contracts. Consider the competitive cluster of AI health platforms. Companies like Spring Health, focusing on mental health, are increasingly demonstrating clinical efficacy, but the translation of these outcomes into auditable financial performance for VBC remains a key challenge for many in the mental health space. Similarly, while iRhythm Technologies has FDA clearances for its SaMD and is actively addressing regulatory observations, the specific VBC contract requirements for demonstrating cost reduction beyond diagnostic accuracy are distinct. Rock Health digital health funding reports Platforms primarily focused on engagement or wellness, such as Noom, BetterHelp, Calm, Headspace, and Oura, often generate impressive user satisfaction and adherence data. However, converting these metrics into the hard, auditable financial savings and peer-reviewed clinical outcomes that payers demand for VBC is a different endeavor. While these tools may play a role in a broader care continuum, their direct qualification for VBC contracts is often limited by the absence of the rigorous evidence package. Hemant Taneja, a prominent investor in AI health, has consistently highlighted the need for AI solutions to deliver measurable value, not just technological novelty. This sentiment directly underpins the VBC readiness gap.

Regulatory and Payer Expectations: The Unforgiving Gatekeepers

The regulatory landscape, driven by entities like CMS and NCQA, is increasingly demanding for technologies seeking to integrate into VBC. CMS VBC Rules and NCQA Standards emphasize evidence-based practices and demonstrable improvements in quality and cost. Payers, represented by organizations like AHIP, are becoming more sophisticated in their contracting, moving beyond simple per-member-per-month (PMPM) fees to intricate performance-based agreements. The absence of a robust data moat, which Hello Heart has effectively built through years of outcomes research, leaves many AI health platforms vulnerable. Without proprietary, peer-reviewed data demonstrating clinical and financial impact, these platforms struggle to differentiate themselves in a crowded market and meet the stringent requirements of VBC contracts. The path to VBC eligibility is not merely about having an AI; it’s about having an AI whose impact is meticulously measured, validated, and guaranteed.

Closing the Gap: The Path Forward

For the estimated 80% of AI health platforms that currently cannot qualify for VBC contracts, the path forward requires a strategic pivot. This isn’t about abandoning innovation but about aligning innovation with the fundamental requirements of value. Key steps include:

• **Prioritizing Outcomes Research:** Dedicating significant resources to designing and executing studies that generate peer-reviewed clinical and financial outcomes data. This needs to be an upfront investment, not an afterthought.
• **Developing Robust Data Infrastructure:** Building systems capable of collecting, analyzing, and securely managing multi-year, risk-adjusted patient data, adhering to standards like HIPAA, HITRUST, and SOC 2.
• **Engaging with Payers Early:** Understanding specific payer requirements for VBC contracts and tailoring evidence generation to meet those needs.
• **Considering Performance Guarantees:** Being prepared to stand behind the platform’s ability to deliver measurable value through contractual commitments.

Companies like Commure, focused on healthcare infrastructure, may indirectly facilitate this by providing platforms for data integration and analysis, but the onus remains on the AI health solution itself to generate the primary evidence. The market is maturing, and the days of securing large contracts solely on the promise of AI are dwindling. For investors and health plan executives, the message is clear: scrutinize the evidence. Without peer-reviewed outcomes, auditable ROI, and performance guarantees, an AI health platform’s VBC aspirations will remain largely unfulfilled. AHIP’s perspective on digital health in VBC The future of AI in healthcare, particularly within value-based models, belongs to those who can prove their worth not just in code, but in concrete, measurable improvements to patient health and healthcare economics.